Vanguard Capital Management
ACTU icon

Vanguard Capital Management’s Actuate Therapeutics ACTU Stock Holding History

Vanguard Capital Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$307K Hold
393,433
– – ﹤0.01% 3749
2026
Q2 		$602K Sell
393,433
-7,096
-2% -$16.4K ﹤0.01% 3684
2026
Q1 		$1.1M Buy
+400,529
New +$1.66M ﹤0.01% 3524

Other funds holding ACTU

BIOS Capital Management
BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Texas Capital Bank Wealth Management Services
Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Rock Creek Group
Rock Creek Group Washington, District of Columbia $1.04B AUM 6.61% 1-Year Est. Return
SFMG Wealth Advisors
SFMG Wealth Advisors Plano, Texas $1.66B AUM 20.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Empowered Funds
Empowered Funds Havertown, Pennsylvania $21.7B AUM 41.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management's ACTU Position: Q3 2026 in Review

Vanguard Capital Management held its Actuate Therapeutics (ACTU) position steady in Q3 2026 at 393,433 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

Vanguard Capital Management first reported a position in ACTU in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.1M in Q1 2026. 31 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

  • Vanguard Capital Management held 393,433 shares of Actuate Therapeutics worth $307K as of Q3 2026.
  • Vanguard Capital Management left its Actuate Therapeutics share count unchanged in Q3 2026.
  • Actuate Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3749 holding.
  • Vanguard Capital Management first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Actuate Therapeutics position peaked at $1.1M in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.